for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Neuralstem, Inc.

CUR.OQ

Latest Trade

1.35USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.10

 - 

24.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.35
Open
--
Volume
--
3M AVG Volume
2.52
Today's High
--
Today's Low
--
52 Week High
24.00
52 Week Low
1.10
Shares Out (MIL)
2.64
Market Cap (MIL)
3.43
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Neuralstem Q2 Loss Per Share $1.45

Intracoastal Capital LLC Reports 9.99% Passive Stake In Neuralstem Inc As Of July 30

Neuralstem Announces Pricing Of $7.5 Mln Underwritten Public Offering

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Neuralstem, Inc.

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

Industry

Biotechnology & Drugs

Contact Info

20271 Goldenrod Ln Ste 2024

+1.301.3664841

https://www.neuralstem.com/

Executive Leadership

Kenneth C. Carter

Executive Chairman of the Board

Cristina Csimma

Director

Mary Ann Gray

Director

David J. Mazzo

Director

Binxian Wei

Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
222.86
Price To Book (MRQ)
0.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-122.76
Return on Equity (TTM)
-105.08

Latest News

Latest News

BRIEF-Neuralstem Announces First Surgery Completed In Cervical Cohort Of Phase 1 Clinical Trial In Patients With Chronic Spinal Cord Injury

* NEURALSTEM ANNOUNCES FIRST SURGERY COMPLETED IN CERVICAL COHORT OF PHASE 1 CLINICAL TRIAL IN PATIENTS WITH CHRONIC SPINAL CORD INJURY Source text for Eikon: Further company coverage:

BRIEF-Neuralstem Q3 loss per share $0.01

* Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update

BRIEF-Neuralstem Inc appoints two members to its board

* Neuralstem announces the appointment of two new members to the board of directors

BRIEF-Neuralstem Inc gets two additional U.S. patents

* Neuralstem Inc - been awarded two additional patents by United States Patent and Trademark Office Source text for Eikon: Further company coverage:

BRIEF-Neuralstem reports Q2 loss per share $0.39

* Neuralstem reports second quarter 2017 fiscal results and provides clinical and business update

BRIEF-‍CVI investments reports a 8.3 pct passive stake in Neuralstem

* CVI Investments reports a 8.3 percent passive stake in Neuralstem Inc as of July 27, 2017 - SEC filing Source text: (http://bit.ly/2vbUBwE) Further company coverage:

BRIEF-Neuralstem awarded grant by NIH to continue preclinical research into treatment for diabetic neuropathy

* Neuralstem awarded $~1mm grant by NIH to continue preclinical research into the potential of nsi-189 for treatment of diabetic neuropathy Source text for Eikon: Further company coverage:

BRIEF-Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder

* Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder

BRIEF-Neuralstem files for mixed shelf of up to $100 mln

* Neuralstem Inc files for mixed shelf of up to $100 million -sec filing Source text - http://bit.ly/2s17fgR Further company coverage:

BRIEF-Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder

* Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder Source text for Eikon: Further company coverage:

BRIEF-Neuralstem reports Q1 loss per share $0.68

* Neuralstem reports first quarter 2017 fiscal results provides clinical and business update

BRIEF-Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury

* Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury

BRIEF-Neuralstem reports year end 2016 fiscal results

* Neuralstem reports year end 2016 fiscal results and business update

BRIEF-Neuralstem to continue as going concern is dependent on generating cash from the sale of its common stock

* Neuralstem-Co's ability to continue as going concern is dependent on generating cash from the sale of its common stock and/or obtaining debt financing

BRIEF-Tianjin Pharmaceuticals Group International Holdings reports 19.99 pct stake in Neuralstem - SEC Filing

* Tianjin Pharmaceuticals Group International Holdings Co., Ltd reports 19.99 percent stake in Neuralstem Inc - SEC filing Source - (http://bit.ly/2l5LaeR) Further company coverage:

BRIEF-Neuralstem announces a 1-for-13 reverse stock split

* Reverse stock split will become effective on Friday, January 6, 2017 Source text for Eikon: Further company coverage:

BRIEF-Neuralstem reports third quarter 2016 results

* Qtrly loss per share $0.05 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up